Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Clinician-Selected FSH Starting Dose and Mature Oocyte Yield in Predicted Poor Responders (OPTIMAL-DOSE)

17 november 2026 bijgewerkt door: Goksu Goc, American Hospital 2 Kosovo

Association of Clinician-Selected FSH Starting Dose With Mature Oocyte Yield in Women With Predicted Poor Ovarian Response: The OPTIMAL-DOSE Prospective Cohort Study

This is a single-centre, prospective, non-interventional (observational) cohort study examining the association between the clinician-selected starting dose of follicle-stimulating hormone (FSH) and the yield of mature metaphase II (MII) oocytes in women with predicted poor ovarian response (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number [POSEIDON] group 3 or 4) undergoing in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) with a gonadotropin-releasing hormone (GnRH) antagonist protocol. The FSH dose is chosen by the treating physician as part of routine care; the study does not allocate, randomize, or change treatment. The primary outcome is the number of MII oocytes per initiated index cycle. Because dosing is not randomized, analyses are adjusted for measured confounders and address confounding by indication.

Studie Overzicht

Gedetailleerde beschrijving

Randomized evidence in predicted poor responders (a randomized trial in predicted poor responders and the 2024 Cochrane review of individualised gonadotropin dosing) does not show improved live birth from higher follicle-stimulating hormone (FSH) dosing, so this cohort is not designed to establish comparative efficacy; its contribution is a description of real-world dose-response patterns and local gonadotropin use and cost. Consecutive eligible women are enrolled after informed consent for data use, each contributing one index cycle. The exposure is the clinician-selected starting FSH dose, analysed as a continuous variable (per 75 international units [IU]), with categories of 150 IU or less versus more than 150 IU reported descriptively and in sensitivity analyses. The primary analysis is an adjusted negative-binomial regression of the metaphase II (MII) oocyte count on exposure, with adjusted means obtained by marginal standardization and an overlap-weighted propensity analysis as sensitivity. Reporting follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) and REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statements.

Studietype

Observationeel

Inschrijving (Geschat)

160

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • Pristina, Kosovo, 10000
        • American Hospital Kosova
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 42 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Vrouw

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Consecutive women aged 18 to 42 years with predicted poor ovarian response (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) group 3 or 4: anti-Mullerian hormone below 1.2 ng/mL and/or antral follicle count below 5) undergoing a gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle as part of routine clinical care at American Hospital Kosova, each contributing one index cycle.

Beschrijving

Inclusion Criteria:

  1. Woman aged 18 to 42 years.
  2. Predicted poor ovarian response, Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) group 3 (under 35 years) or group 4 (35 years or older): anti-Mullerian hormone (AMH) below 1.2 ng/mL and/or antral follicle count (AFC) below 5 (both ovaries combined).
  3. Planned gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle as part of routine clinical care.
  4. First eligible (index) cycle during the study period; both ovaries present.
  5. Written informed consent for data collection and processing.

Exclusion Criteria:

  1. Predicted normal or high ovarian reserve (AMH 1.2 ng/mL or higher and AFC 5 or higher).
  2. Non-antagonist protocol (for example, long GnRH-agonist).
  3. Oocyte-donation or fertility-preservation (egg-freezing) cycle.
  4. A prior cycle of the same woman already enrolled in the study.
  5. Inability to provide informed consent.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: PROSPECTIVE

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Lower starting dose (150 international units [IU] or less)

Women whose treating physician chose a starting daily follicle-stimulating hormone (FSH) dose of 150 international units (IU) or less as part of routine clinical care (observed, not assigned by the study).

FSH administered per routine clinical practice; the starting dose is selected by the treating physician (observed exposure, not assigned by the study). Starting dose is analysed continuously (per 75 IU), with categories of 150 IU or less versus more than 150 IU reported descriptively.

Higher starting dose (more than 150 IU)

Women whose treating physician chose a starting daily FSH dose of more than 150 IU (typically 225 IU) as part of routine clinical care (observed, not assigned by the study).

FSH administered per routine clinical practice; the starting dose is selected by the treating physician (observed exposure, not assigned by the study). Starting dose is analysed continuously (per 75 IU), with categories of 150 IU or less versus more than 150 IU reported descriptively.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of mature metaphase II (MII) oocytes retrieved
Tijdsspanne: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)

Number of metaphase II (MII) oocytes retrieved per initiated index ovarian stimulation cycle, assessed by the embryologist at a standardized time after oocyte retrieval. Compared across the clinician-selected starting-dose exposure using adjusted analysis (associations, not causal effects). Cycles cancelled before oocyte retrieval contribute zero MII oocytes in the initiated-cycle analysis. Oocytes matured in vitro are excluded from the primary count.

On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Total follicle-stimulating hormone (FSH) activity administered
Tijdsspanne: From the first to the last day of ovarian stimulation (up to 21 days)

Total follicle-stimulating hormone (FSH) activity administered during the index stimulation cycle, in international units (IU), by observed starting-dose exposure. FSH activity is recorded separately from luteinizing hormone (LH) and human chorionic gonadotropin (hCG) activity.

From the first to the last day of ovarian stimulation (up to 21 days)
Gonadotropin medication cost
Tijdsspanne: From the first to the last day of ovarian stimulation (up to 21 days)

Cost of the gonadotropin medication used during the stimulation cycle, in euros (EUR), calculated using a pre-specified standardized unit-price table, by observed starting-dose exposure.

From the first to the last day of ovarian stimulation (up to 21 days)
Total number of oocytes retrieved
Tijdsspanne: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)

Total number of oocytes retrieved at oocyte pick-up per initiated index cycle, by observed starting-dose exposure.

On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
Oocyte maturity rate
Tijdsspanne: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)

Ratio of the number of metaphase II (MII) oocytes to the total number of oocytes retrieved in the index cycle, by observed starting-dose exposure.

On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
Cycle cancellation before oocyte retrieval
Tijdsspanne: From the first day of ovarian stimulation to the planned day of oocyte retrieval (up to 21 days)

Whether the initiated index cycle was cancelled before oocyte retrieval, by observed starting-dose exposure.

From the first day of ovarian stimulation to the planned day of oocyte retrieval (up to 21 days)
Duration of ovarian stimulation
Tijdsspanne: From the first to the last day of ovarian stimulation (up to 21 days)

Number of days of ovarian stimulation during the index cycle, by observed starting-dose exposure.

From the first to the last day of ovarian stimulation (up to 21 days)
Number of normally fertilised oocytes with two pronuclei (2PN)
Tijdsspanne: At the fertilisation check, 1 day after oocyte retrieval (up to 22 days after the start of ovarian stimulation)

Number of oocytes showing two pronuclei (2PN) at the fertilisation check in the index cycle, by observed starting-dose exposure.

At the fertilisation check, 1 day after oocyte retrieval (up to 22 days after the start of ovarian stimulation)
Number of usable embryos
Tijdsspanne: Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)

Number of embryos from the index cycle that are transferred, cryopreserved or biopsied, meeting the minimum grade of the pre-specified laboratory standard, by observed starting-dose exposure. Each embryo is counted once.

Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)
Number of blastocysts
Tijdsspanne: Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)

Number of embryos from the index cycle reaching the blastocyst stage, by observed starting-dose exposure.

Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Live birth (exploratory)
Tijdsspanne: Up to 12 months after the start of ovarian stimulation

Delivery of at least one live-born infant, recorded per initiated index cycle and per transfer. Exploratory only; the study is not powered for this outcome and it is highly susceptible to confounding by indication. Reported descriptively.

Up to 12 months after the start of ovarian stimulation
Clinical pregnancy (exploratory)
Tijdsspanne: At 7 weeks of gestation (approximately 5 weeks after the first embryo transfer)

Presence of an intrauterine gestational sac on ultrasound after the first fresh or frozen embryo transfer from the index cycle, recorded per initiated index cycle and per transfer. Exploratory only; the study is not powered for this outcome. Reported descriptively.

At 7 weeks of gestation (approximately 5 weeks after the first embryo transfer)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 november 2026

Primaire voltooiing (Geschat)

1 oktober 2028

Studie voltooiing (Geschat)

1 augustus 2029

Studieregistratiedata

Eerst ingediend

11 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

17 november 2026

Eerst geplaatst (Werkelijk)

18 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

17 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren